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Suwtuenv
The primary aim of this thesis was to collect information and to provide nerv eviden-
ce for monitoring and counsell ing of women of childbearing age who have been or
areexposed to acitretin. The studies in the present thesis lvere all init iated after the
alert on the teratogenic dermatological agent acitretin in October 1990, when it was
notif ied that unexpectedly, the l ipophil ic compound etretinate was found in plasma
of acitretin users. This resulted in an extension of the recommended post-therapv
contraception period from 2 months to 2 years, which inevitably had a large impact
on acitretin exposed women of childbearing age. In this thesis the evaluation of com-
munication processes, the frequency of the presence of etretinate, the identif ication of
riskf'actors a sociated with the presence of acitretin into etretinate, and the toxicolo-
$c and teratogenic risks of acitretin are discussed.
In chapter 2, the position of the postmarketing surveil lance study on acitretin,
which is an ad-hoc field-study, is described with respect to the curently available
systems, sources and methods for postmarketing sun,eil lance. Field-studies appear to
beold-fashioned, and have many disadvantages uch as tinre, cost and validity. How-
ever, d ue to their potentia I to study ra re ou tcomes o r exposure, a nd their f lexibil i ty in
measuring different outcomes, ',vhich otten cannot be measured in automated data-
bases, such as plasma levels of specific drug, quality of l i fe or benefits of drugs, ad-hoc
field-studies sti l l  deserve a place in nrodern pharmaco-epidemiotogy. In addition to
the different systems, novel methods in (p.[3s1aco)-epidemiology such as the case-
cÍossover, nested case-control and case-cohort designs are brieÍ' ly described. [n this
thesis the follow-up, case control and case-crossover design were applied.
ln chapter 3 the preclinical, cl inical, and postmarketing experience with acitretin
therapy are delineated. The historical development of retinoids was based on the tox-
ici$/efficacy ratio and evolved from vitamin A to the first (isotretinoin), second (etret-
inate, acitretin) and to the third generation retinoids (motretinide). The molecular
mahanism oiaction is not fully elucidated yet. Acitretin is merely used for the treat-
ment of keratinization disorders such as psoriasis, ichthyosis, Darier's disease etc.
Àcihetin is a l ipophil ic compound which is extensively bound to plasma proteins
(>9%). Oral absorption is variable and dependent on fbod, acitretin does not accu-
mulate in fat and has an elimination half-l i fe of about 50 h. It is metabolised by
hunerization t  the cis-isorner, oxidation and finally glucuronidation. Apparently,
lcihetincan be esterif ied to its ethanol-ester etretinate. The toxicity resembles the pat-
hmof eft 'ects observed in the hypervitaminosis A syndrome and include, mucocu-
hneous, hepato, visual, and central nervous toxicity and is often a reason to quit ther-
{y,The most important disadvantage of acitretin is its teratogenic potency, which is
hemoiive for the majority of studies in this thesis. Most of the problenrs concerning
heteratogenic potency are related to uncertainties: the duration of the period of ex-
s$teÍatogenic risk after discontinuation of acitretin, and the teratogenic threshold
hplasma of acitretin and etretinate are sti l l  unknown.
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In chapter 4, we discuss how an ad-hoc cohort of acitretin-exposed women of
childbearing age was recruited following the alert on acitretin. Recruitment occurred
by dermatologists, and pharmacists plus dispensing general practit ioners (GPs). We
described the velocity oí and response to the recruitment procedures, and the repre-
sentativeness of the recruited cohort. It was also studied whether the individuals who
gave informed consent would have preferred to be recruited by either dermatologists
or pharmacists, and whether the information obtained from pharmacists and dispens-
ing CPs was valid. The results of this studv show that pharmacists and dispensing
CPs (drug dispensers) recruited fast, with none or l i tt le selection and attained 42% re-
sPonse. Dermatologists recruited slow, selective and with ZA'Ilt rcsponse. The majority
of women (60%) recruited by dermatologists would have given informed consent if
they were recruited by their pharmacist, as l ikely.
In chapter 5, the communication procedures and effects were evaluated which fol-
lowed the alert on acitretin. The penetration of direct mail from the health authorii ies
and from the pharmaceutical company ranged Írom 97-98u1, and 6s-94'I, among
health professionals. The population at risk was intbrmed via personal communica'
tion with health professionals, and,/or the mass media. of the wornen at risk. 19%
were contacted by the dermatologSst, 3001, by the GP, and 39,/n by the pharmacist,
357o was never informed by an_y health professional. The results of this study shorv
that the Dutch health care system is adequately equipped fbr eff 'ective communica-
tion between health authorit ies, pharmaceutical industry and health professionais.
Due to problems with identif ication according to past exposure, subsequent personal
communication between health prof'essionals and the population at risk was inade-
quate. This study shows that the role of pharmacists in personal communication
should be increased, as they can rapidly identify persons at risk as a result of previous
exposure to specific drugs.
In chapter 6, an overview is given of the different niethods to measure and define
drug exposure. Throughout this thesis we used the legend tluration nrethoci todeí' ine
exPosure to acitretin. Sources íbr collection of data on drug intake were interview
data, medical records and plasma levels. The reliabil i ty of the methods was good as
was calculated in appendix B.
In chapter Z uti l ization characteristics of acitretin were described. In addition it
was investigated whether those uti l ization characteristics changed after the alerton
the extended contraception period. The results showed that women who suffered
from severe non-psoriatic keratinization disorders were expose<1 to acitÍetin moÍ?
(longer) during the study period. Also they were more likely to have used etretinate
in the past, were more compliant, but they were not prescribed higherdailydCIages
than women suffering from psoriasis.
In chapter 8, we estimated the frequency of plasma etretinate concentrationsin
women of childbearing age who were treated with acitretin. A cross-sectional study,
and a one-year follow-up study were conducted in l8i and 62 women, respectively.
Two analytical assays, with different l imits of detection were used to measure plasm
etretinate and acitretin concentrations. The init ial, commonly used assay (l imit of de
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ers of acitretin, and a small cumulative incidence of etretinate in plasnra (30'/, ' ,91"-,"
\ZYr,47'k,). The second assav (l imit of detection of 0.1ng/ml), resulted in more consis-
tent, reproducible point prevalences (range: 64-77"/,,), at the different sarnpling times.
The 9-months cumulative incidence was 78ol' (Cley,;(í)'I,,96"1,). Among stoppers of
acitretin therapy the drug was detectable in plasma up to 30 months after discontinu-
ance. This study showed that nearly all female users of acitretin have significant etret-
inate plasma concentrations, and etretinate or its metabolite are detected in plasma
much longer than the expected nraximum of 2 years.
ln chapter 9, the predictive value of plasma etretinate measurements in compari-
son with the presence of etretinate in fat was measured. The prevalences oÍ detect-
able etretinate concentrations were 45"/' and tl3'/,, \n plasma a nd subcutaneous tissue,
resPectively, among current acitretin users and lt l1a and 116% among those who had
stopped acitretin therapy. lnabil ity to detect plasma etretinate is a poor predictor for
theabsence of etretinate in fat. Acitretin and/or etretinate were detectable in fat and
insome cases in plasma front women who had ceased acitretin therapy fbr up to 29
rnonths.
ln chapter 10, we describe the implementation of the analytical method to deter-
mine tretinate and acitretin simultaneously in plasma, fat and liver t issue of rats.
Ïhisanalysis was set up to conduct an experiment with the aim to investigate the ef-
kbof fasting, or food deprivation, on etretinate and acitretin plasma concentrations
of rab which were previously loaded with etretinate. Knowledge of the effect of fast-
ingon the disposition of etretinate might be useful for counsell ing of women with
etretinate subcutis concentrations who want to become pregnant. This pilot experi-
ment showed that fasting or loss of rveight after etretinate treatment may quickly
raiseacitretin (metabolite) plasma levels. Upon extrapolation to humans, these find-
inpcould contribute to monitoring of women, since a short period of fasting might
yield detectable plasma levels.
In chapter 11., we describe the study which aimed to identif-y risk factors which are
nsociated with the presence ot etretinate in plasma of acitretin users. Risk factors
wtn sought in factors which might influence absorption, distribution and metabo-
bmof acitretin and included diet, demographics, medical history, drug and alcohol
hbke,smoking, abnormal blood chenristry, prior etretinate treatment, and recency of
ritretin i take. Out of the 181 females, 52 (29"1,) were currently exposed to acitretin.
hthetotal of 1{:t1, 23 ('13'/o) women had etretinate levels above 1 nglml. Variables
rhichwere independent predictors for the presence of etretinate in plasma included
exposure to acitretin (OR=43, Cle;,x,: 9.5, 3tt7); high accumulated intake of
(OR=26, CIe6y 5.0, 247); more than 2 glasses of alcohol per day (OR=10
1.2,121), past exposure to etretinate (OR=tt.8 CIes,7" 2,9,32); Quetelet indices
30 (kg/mf (OR=5.5 CIer7. 1.01, 25), suffering of heartburn (OR=4.2 CIe57" 1.5,
intake of acitretin in the evening (OR=4.5, Cle5y" 1.7,3t1), concomitant intake of
protein-bound drugs (OR=3"9, Clq,i":1.1-13), more than 5 prescriptions of Cyt
inducing drugs concomitant with acitretin (OR= 3.5, CIes.7":1.0-14), and abnor-
low serum protein levels (OR:3.9 Cler,7,,:1.1-13). High intake of mono-disaccha-






the high intake of saturated fat, singular unsaturated fat, and animal protein was as-
sociated with the presence of etretinate in plasma (ORo61=17, C19,,7 1.7, 18),
(ORu6; = 10.7, 1.7) a nd (ORu6i=7 .7, Cle<,7" 1 .7, 56), respectively.
In chapter L2, a 2}-week-old male fetus is described with multiple congenital
anomalies who was exposed to acitretin in the first trimester of pregnancy. The fetus
showed severe symmetric anomalies of upper and lower l imbs, mandibuiofaciai
dysostosis l ike craniofacial anomalies, ear anomalies and an ASD. Although the cra-
niofacial anomalies resemble the maltbrmation observed in the classic 'retinoic acid
embryopathy', l imb malformations were seldomly reported after maternal use of vita-
min A congeners. This case emphasises again that extreme care and precaution are
needed before prescribing a potentially teratogenic drug to a ferti le woman.
In chapter L3, we describe the methodology of follow-up and investigation oÍ
pregnancy outcomes in a fixed population-based acitretin exposuÍe cohort in the
Netherlands. Children conceived within and after the Lyear post-therapy contracep-
tion, who originated from the prospective cohort were examined for major and minor
malformations at the age of 1.5-2 years. ln total 2ll pregnancies occurred in the cohort,
16 within, and 12 aíter 2 years post-therapy. Of the women at risk to beconie preg-
nant 10% conceived within two years. Seven wome n (5%) conceived despite the use
of contraceptives, 6 of them had used low dose oestrogen pil ls. In total 6 pregnancies
ended in a spontaneous, and 4 in an elective abortion. The percentage of pregnancies
ending in spontaneous abortions did not substantially differ in the series conceived
within and after 2 years, respectively. A total of lU l iveborn babies are potentially
available for dysmorphologic examination. The six children examined 
,yet, all showed
minor malformations, whereas 3 showed more serious medical problems. Although
we could not make inferences on the malformatiorrs associated with the previous use
of acitretin yet, this study showed that too manV women got pregnant within the rec-
ommended two year contraception period. Hence. adequate contraception and po-
tential threats to its efficacy need to be surveil led closely by physicians and pharma-
cists.
In chapter 14, we described the dysmorphology and neurobehavorial charac-
teristics of a 9-year old boy whose mother conceived 1(l months after cessation Í
etretinate therapy. The boy shows a few minor craniofacial malfbrmations which
have been associated with the retinoic acid embryopath-y. In addition his intell igence
is far below normal (lQ: 68) and difficulties exist in those neurologic functions, which
also seem to be affected mostoften after isotretinoin exposure. This reportshowsthat
potentially etretinate, and acitretin as its teratogenic metabolite may cause neuroh-
havioral problems.
In chapter 15, we aimed to make a rough inventory of the known and unknown
side effects of acitretin experienced by women of childbearing age. Spontaneously n.
ported, but hitherto unknown effects included changes of pigmentation, eczema,
change of temper/ mood/ concentration, vertigo, edema, arrhythmia, vulvo-vaginal
infection, and more serious blood loss during menstruation. The crude cumulative in-
cidence of systematically asked known adverse effects corresponded with the le
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hair which were all reported more freguently. Among the systematically asked hith-
erto unknown adverse effects, vulvo-vaginal infection (21u1,), and paraesthesia (18%)
were reported most often by our study population. Vertigo was reported by 11,/,, of
the women. Vertigo and vulvo-vaginal infections were perceived as ntost severe,
whereas only the latter condition was largely treated with tnedications.
In chapter 16, we estimated the risk of vulvo-vaginal candidiasis among the users
of acitretin through prescription sequence analysis. The positi, ' ,e predictive value of
the proxy drug tor vulvo-vaginal candidiasis ranged between 57-1007(,, the sensitivity
was87'k, and the specificity was99()1,. The crude incidence rate ratio for vulvo-vaginal
candidiasis fbllorving acitretin exposure was 2.t3(CIe57:1.1-7.1). The pooled Mantel-
Haenszel incidence rate ratio was 3.3(Cler.7":1.1-9.6) after stratif ication ior accumulated
level of exposure. Patient-stratif ied analysis on the subgroup of cases (n=15) revealed
anodds ratio of 6.5 (CIe57":2.3-18.2).
ln chapter 17, a tollow-up study is presented which describes the association be-
tween acitretin and the occurrence of medically treated vertigo. Although not signifi-
cantly, the relative risk of vertigo was increased during acitretin exposure (6.1 , Cle5V:
0.78-50.8). Vertigo was perceived as very serious by the patients, therefore additional
studies should be done with a larger sample size as to further explore this suggested
association.
In chapter L8, we intended to measure the perception of teratogenic risk of
acihetin by the women, physicians and regulatory authorit ies in three situations,
which diifered as regards time of discontinuance of therapy and plasma
acihetirVetretinate lev ls. The results shor,ved that there is an unjustif ied reliance on
lhe safety of the 2 year criterium. Conception whilst acitretin was detectable in
plasma was perceived most risky, most respondents perceived the risk as much to ex-
hemely higher compared to the average risk. The risk of malformations upon concep-
tionwithh 2years was considered higher than thatafter two years. The riskpercep-
tion of the regulatory authority was fully in l ine with the womens' and physicians'
ptceptions. Communication about their own plasma levels did not change the risk
petception of women, however, half of the women wanted additional information.
kveral studies in this thesis have shown that personal communication with the
ptients at risk is not always up to standard, mostly since it is diff icult tbr physicians
bidentiÍy users of a specific drug. In addition it was shown throughout this thesis
that the frequency of the presence of etretinate in plasma and fat is high, that acitretin
cnbe converted into etretinate in the body and that the period of excess risk can be
hnger than 2 years. It was shown that plasma measurements are not capable of pre-
dicting the absence of etretinate in fatty tissue vely well, and that the frequency of
ektinate as well as the predictive value depend highly on the analytical method be-
lngapplied. Etretinate might be mobil ized due to loss of weight, and potentially other
hcton. we observed that acitretin very l ikely is a human teratogen and may also
muse neurobehavioral problems. Following our results, women of childbearing age
should not be prescribed acitretin. The women who already use acitretin anrl want to
mnceive should refrain fronr alcohol and other identified risk factors for the presence
dehetinate, they should be told that the period of excess risk may be longer than 2
u1
Summary
years, as to prevent unjustified reliance. They should be offered monitoring in plasma
and subsequently fat t issue by means of the most sensitive analytical assay, with a
limit of detection of 0.1 ng/ml preferably.
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